Literature DB >> 25037612

Role of pancreatic juice cytology in the preoperative management of intraductal papillary mucinous neoplasm of the pancreas in the era of international consensus guidelines 2012.

Takao Ohtsuka1, Taketo Matsunaga, Hideyo Kimura, Yusuke Watanabe, Koji Tamura, Noboru Ideno, Teppei Aso, Yoshihiro Miyasaka, Junji Ueda, Shunichi Takahata, Takashi Osoegawa, Hisato Igarashi, Tetsuhide Ito, Yasuhiro Ushijima, Fumihiko Ookubo, Yoshinao Oda, Kazuhiro Mizumoto, Masao Tanaka.   

Abstract

BACKGROUND: Routine endoscopic retrograde pancreatography (ERP) for pancreatic juice cytology (PJC) during management of intraductal papillary mucinous neoplasm (IPMN) is not recommended in the international consensus guidelines 2012. The aim of the present study was to investigate the roles of PJC in relation to the new stratification of clinical findings in the consensus guidelines 2012.
METHODS: Medical records of 70 consecutive patients who underwent preoperative PJC, subsequent pancreatectomy, and a pathological diagnosis of IPMN were reviewed. Diagnostic ability of PJC to detect malignant lesions was calculated by the stratification of clinical findings.
RESULTS: Forty patients had malignant lesions, including 29 with malignant IPMN, 10 with concomitant pancreatic adenocarcinoma, and one with both. Accuracies of PJC in all 70 patients and in 59 patients with IPMN alone were 77 and 80 %, respectively. The sensitivity and accuracy of PJC in patients with "worrisome features" were 100 and 94 %, respectively. Eight of 11 patients with concomitant pancreatic adenocarcinoma had non-malignant IPMN without risk factors, and 3 significant lesions could be diagnosed only by ERP/PJC. In addition, the management plan based on imaging study changed from observation to resection in two patients who had the single "worrisome feature" of branch duct IPMN and positive PJC results. As a result, PJC altered the management plan in 5 patients.
CONCLUSIONS: Pancreatic juice cytology potentially has important roles to determine the adequate treatment choice in patients with IPMNs with "worrisome features," and to detect significant lesions that could not be detected by other imaging modalities.

Entities:  

Mesh:

Year:  2014        PMID: 25037612     DOI: 10.1007/s00268-014-2684-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  32 in total

1.  The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Seiko Hirono; Masaji Tani; Manabu Kawai; Ken-ichi Okada; Motoki Miyazawa; Atsushi Shimizu; Yuji Kitahata; Hiroki Yamaue
Journal:  Ann Surg       Date:  2012-03       Impact factor: 12.969

Review 2.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

3.  Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Suresh T Chari; Dhiraj Yadav; Thomas C Smyrk; Eugene P DiMagno; Laurence J Miller; Massimo Raimondo; Jonathan E Clain; Ian A Norton; Randall K Pearson; Bret T Petersen; Maurits J Wiersema; Michael B Farnell; Michael G Sarr
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

4.  Does preoperative cross-sectional imaging accurately predict main duct involvement in intraductal papillary mucinous neoplasm?

Authors:  M R Barron; A M Roch; J A Waters; J A Parikh; J M DeWitt; M A Al-Haddad; E P Ceppa; M G House; N J Zyromski; A Nakeeb; H A Pitt; C Max Schmidt
Journal:  J Gastrointest Surg       Date:  2014-01-09       Impact factor: 3.452

5.  An increase in the number of predictive factors augments the likelihood of malignancy in branch duct intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Takao Ohtsuka; Hiroshi Kono; Yosuke Nagayoshi; Yasuhisa Mori; Kosuke Tsutsumi; Yoshihiko Sadakari; Shunichi Takahata; Katsuya Morimatsu; Shinichi Aishima; Hisato Igarashi; Tetsuhide Ito; Kousei Ishigami; Masafumi Nakamura; Kazuhiro Mizumoto; Masao Tanaka
Journal:  Surgery       Date:  2011-08-27       Impact factor: 3.982

6.  Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes.

Authors:  Mari Mino-Kenudson; Carlos Fernández-del Castillo; Yoshifumi Baba; Nakul P Valsangkar; Andrew S Liss; Maylee Hsu; Camilo Correa-Gallego; Thun Ingkakul; Rocio Perez Johnston; Brian G Turner; Vasiliki Androutsopoulos; Vikram Deshpande; Deborah McGrath; Dushyant V Sahani; William R Brugge; Shuji Ogino; Martha B Pitman; Andrew L Warshaw; Sarah P Thayer
Journal:  Gut       Date:  2011-04-20       Impact factor: 23.059

7.  Pancreatic juice cytology and subclassification of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Yasuhiro Hibi; Noriyoshi Fukushima; Akihiko Tsuchida; Atsushi Sofuni; Takao Itoi; Fuminori Moriyasu; Kiyoshi Mukai; Tatsuya Aoki
Journal:  Pancreas       Date:  2007-03       Impact factor: 3.327

8.  Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.

Authors:  Ken Kamata; Masayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Kumpei Kadosaka; Takeshi Miyata; Hajime Imai; Kiyoshi Maekawa; Takaaki Chikugo; Masashi Kumano; Tomoko Hyodo; Takamichi Murakami; Yasutaka Chiba; Yoshifumi Takeyama
Journal:  Endoscopy       Date:  2013-11-11       Impact factor: 10.093

9.  Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.

Authors:  Noboru Ideno; Takao Ohtsuka; Hiroshi Kono; Kenji Fujiwara; Yasunori Oda; Shinichi Aishima; Tetsuhide Ito; Kousei Ishigami; Shoji Tokunaga; Kenoki Ohuchida; Shunichi Takahata; Masafumi Nakamura; Kazuhiro Mizumoto; Masao Tanaka
Journal:  Ann Surg       Date:  2013-07       Impact factor: 12.969

10.  Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.

Authors:  Koji Tamura; Takao Ohtsuka; Noboru Ideno; Teppei Aso; Koji Shindo; Shinichi Aishima; Kenoki Ohuchida; Shunichi Takahata; Yasuhiro Ushijima; Tetsuhide Ito; Yoshinao Oda; Kazuhiro Mizumoto; Masao Tanaka
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

View more
  7 in total

1.  Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society.

Authors:  Seiko Hirono; Yasuhiro Shimizu; Takao Ohtsuka; Toshifumi Kin; Kazuo Hara; Atsushi Kanno; Shinsuke Koshita; Keiji Hanada; Masayuki Kitano; Hiroyuki Inoue; Takao Itoi; Toshiharu Ueki; Toshio Shimokawa; Susumu Hijioka; Akio Yanagisawa; Masafumi Nakamura; Kazuichi Okazaki; Hiroki Yamaue
Journal:  J Gastroenterol       Date:  2019-08-28       Impact factor: 7.527

2.  The validity of the surgical indication for intraductal papillary mucinous neoplasm of the pancreas advocated by the 2017 revised International Association of Pancreatology consensus guidelines.

Authors:  Yusuke Watanabe; Sho Endo; Kazuyoshi Nishihara; Keijiro Ueda; Mari Mine; Sadafumi Tamiya; Toru Nakano; Masao Tanaka
Journal:  Surg Today       Date:  2018-06-30       Impact factor: 2.549

Review 3.  Pancreatic cystic neoplasms: Review of current knowledge, diagnostic challenges, and management options.

Authors:  Tanima Jana; Jennifer Shroff; Manoop S Bhutani
Journal:  J Carcinog       Date:  2015-03-14

Review 4.  Current roles of endoscopy in the management of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Masao Tanaka
Journal:  Dig Endosc       Date:  2015-02-05       Impact factor: 7.559

Review 5.  Surgical strategy for intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Seiko Hirono; Hiroki Yamaue
Journal:  Surg Today       Date:  2019-12-05       Impact factor: 2.549

6.  Validation of international consensus guideline 2012 for intraductal papillary mucinous neoplasm of pancreas.

Authors:  Dong Hyeon Han; Huisong Lee; Jin Young Park; Wooil Kwon; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi
Journal:  Ann Surg Treat Res       Date:  2016-02-26       Impact factor: 1.859

7.  Efficacy and Safety of Pancreatic Juice Cytology with Synthetic Secretin in Diagnosing Malignant Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Yohei Takeda; Kazuya Matsumoto; Takumi Onoyama; Taro Yamashita; Hiroki Koda; Wataru Hamamoto; Yuri Sakamoto; Takuya Shimosaka; Shiho Kawahara; Yasushi Horie; Hajime Isomoto
Journal:  Diagnostics (Basel)       Date:  2022-03-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.